Form 4: Spyre Therapeutics Insider Trades: Sloan Sheldon Sells Shares

Sloan Sheldon, Chief Medical Officer of Spyre Therapeutics, Inc., reported transactions involving the sale of common stock and the acquisition of stock options under a Rule 10b5-1 trading plan.

Summary

• Sloan Sheldon, Chief Medical Officer at Spyre Therapeutics, Inc. (SYRE), engaged in stock transactions on July 1, 2026.
• Sheldon acquired 8,334 shares of common stock at a price of $27.46 per share, executed under a Rule 10b5-1 trading plan adopted on June 20, 2025.
• Additionally, Sheldon sold 6,500 shares at a weighted average price between $87.03 and $87.99, and another 1,834 shares at a weighted average price between $88.03 and $88.95.
• Sheldon also holds a stock option representing the right to purchase 400,000 shares of common stock, with vesting scheduled to occur over three years starting October 1, 2025, contingent on continued employment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports routine insider transactions under a pre-established plan, without providing new strategic or financial information.

Positives

• Acquisition of 8,334 shares at a favorable price of $27.46, potentially indicating continued belief in the company's long-term prospects.
• The transactions were conducted under a Rule 10b5-1 trading plan, suggesting a pre-determined and structured approach to stock sales, which can mitigate concerns about insider trading based on material non-public information.

Negatives

• Significant sale of 8,334 shares at a price of $27.46, which is considerably lower than the sale prices reported.
• Sale of a substantial number of shares (6,500 and 1,834) at prices significantly higher than the acquisition price, indicating a realization of gains by the executive.

Risks

• The Rule 10b5-1 plan was adopted on June 20, 2025, and the transactions occurred on July 1, 2026, indicating a potential gap between plan adoption and execution.
• The weighted average pricing for sales suggests that the executive may have sold shares at varying price points, making it difficult to ascertain the exact profit realized on each individual sale without further disclosure.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by Spyre Therapeutics' Chief Medical Officer is a common strategy for executives to diversify their holdings or manage personal finances while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders may view the sale of shares by an executive with mixed feelings, though the use of a 10b5-1 plan can mitigate negative perceptions.
• Employees may be indirectly impacted by executive stock sales, depending on the underlying reasons and the company's performance.

Key Dates

Keywords

Form 4, Insider Trading, Spyre Therapeutics, SYRE, Sloan Sheldon, Stock Options, Rule 10b5-1, Beneficial Ownership, Securities Exchange Act